What it does
The company states that it is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. Its products and development candidates address eye, allergic and inflammatory, cancer, cardiovascular and metabolic, neurological, hematologic, infectious, and rare diseases. The filing describes a strategy built on scientific research and drug development technologies, supplemented by clinical development, manufacturing, and commercial capabilities. Its approved-product list includes EYLEA HD, EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Evkeeza, Ordspono, Lynozyfic, and other products; the company and collaborators develop additional candidates in clinical development.
Source: Regeneron Pharmaceuticals, Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov
How it makes money
The filing presents revenue from product sales and collaboration arrangements. For products discovered by Regeneron, net product sales may be recorded by the company, a collaborator, or a licensee. The company records U.S. sales of EYLEA HD and EYLEA, while Bayer records sales outside the United States; the company records its share of related outside-U.S. profits in collaboration revenue. Sanofi records global Dupixent and Kevzara sales, with the company recording its share of profits in collaboration revenue. The company records global Libtayo sales and pays Sanofi a royalty, while it records U.S. Praluent sales and receives royalties from Sanofi’s sales outside the United States.
Source: Regeneron Pharmaceuticals, Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov
Customers and geography
The filing states that the company sells marketed products for which it records net product sales in the United States to distributors and specialty pharmacies. These distributor customers generally sell directly to healthcare providers or other pharmacies. Product approvals listed in the filing span the United States, European Union, and Japan, and certain products are also approved in countries outside those territories. For commercialization responsibilities, Bayer handles EYLEA HD and EYLEA sales outside the United States, while Sanofi handles Praluent outside the United States. The filing uses “ROW” to mean rest of world in its Regeneron-discovered product sales table.
Source: Regeneron Pharmaceuticals, Inc. Form 10-K for fiscal 2025, Item 1 and Item 1A — sec.gov
Competition
The company states that it faces substantial competition from pharmaceutical and biotechnology companies. It says competition among approved products is based on efficacy, safety, reliability, administration, dosing frequency, availability, price, and intellectual-property position, among other factors. The filing names, among others, Genentech/Roche, Novartis AG, Amgen Inc., Sandoz, AbbVie, Eli Lilly and Company, AstraZeneca, GSK, Merck & Co., Inc., Bristol-Myers Squibb, Pfizer, and Roche as competitors for certain marketed products. It also states that product candidates face competition from companies using antibody-generation, RNAi, CAR-T cell, and gene-therapy technologies.
Source: Regeneron Pharmaceuticals, Inc. Form 10-K for fiscal 2025, Item 1 — sec.gov
Key risks
-
The filing states that the company is substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent.
-
Drug development and obtaining and maintaining regulatory approval are described as costly, time-consuming, and highly uncertain.
-
The company states that intellectual-property protections may be insufficient to protect proprietary rights.
-
It relies on limited internal and contracted manufacturing and supply-chain capacity.
-
Product testing or use that harms people, or is perceived to do so, could lead to costly and damaging product-liability claims.
-
Termination or breach of collaborations with Sanofi, Bayer, or other third parties could materially harm development, manufacturing, and commercialization.
Source: Regeneron Pharmaceuticals, Inc. Form 10-K for fiscal 2025, Item 1A — sec.gov
People and operations
The company had 15,410 employees in FY2025. Its operations encompass research, clinical development, manufacturing, and commercialization. The filing states that its ability to compete depends in part on developing safe and effective candidates, completing clinical testing and approval processes, and supplying commercial quantities to the market. It also identifies reliance on limited internal and contracted manufacturing and supply-chain capacity as a risk. The provided filing excerpts do not state facilities or seasonality information.
Source: Regeneron Pharmaceuticals, Inc. Form 10-K for fiscal 2025, Item 1 and Item 1A — sec.gov